Evidence map›Paper›PMID 37232745›Full record

ReviewCurrent issues in molecular biology2023

Cellular and Genetic Background of Osteosarcoma.

Inga Urlić, Marijana Šimić Jovičić, Karla Ostojić, Alan Ivković

Open access · goldAbstract readReview
In one paragraph

Review in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Translational cancer research · 2026
    Article
  4. Antimetastatic Effects of aAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Inga UrlićDepartment of Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0001-7321-2192
Marijana Šimić JovičićDepartment of Paediatric Orthopaedics, Children's Hospital Zagreb, 10000 Zagreb, Croatia.
Karla OstojićDepartment of Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.
Alan IvkovićDepartment of Orthopaedics and Traumatology, University Hospital Sveti Duh, 10000 Zagreb, Croatia.ORCID 0000-0003-0236-6244
University of Zagreb · HRChildren's Hospital Zagreb · HR

Funding

Croatian Science Foundation IP-2018-01-7590Croatian Science Foundation IP-2020-02-9559
6 · The paper itself

Abstract

Osteosarcoma describes a tumor of mesenchymal origin with an annual incidence rate of four to five people per million. Even though chemotherapy treatment has shown success in non-metastatic osteosarcoma, metastatic disease still has a low survival rate of 20%. A targeted therapy approach is limited due to high heterogeneity of tumors, and different underlying mutations. In this review, we will summarize new advances obtained by new technologies, such as next generation sequencing and single-cell sequencing. These new techniques have enabled better assessment of cell populations within osteosarcoma, as well as an understanding of the molecular pathogenesis. We also discuss the presence and properties of osteosarcoma stem cells-the cell population within the tumor that is responsible for metastasis, recurrence, and drug resistance.

Indexed as

cancer stem cellsdriver mutationsosteosarcoma

Identifiers

PMID37232745
PMCPMC10217763
OpenAlexW4376645253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.